HOW CAN WE HELP?

Schedule Free Consultation

    CONTACT US

    Our Locations

    Philadelphia

    1800 JFK Blvd. Suite 1400 Philadelphia, PA 19103

    (215)-666-7777

    Malvern

    101 Lindenwood Dr. Suite 225W Malvern, PA 19355

    (484)-474-9990

    Plymouth Meeting

    600 West Germantown Pike Suite 400W Plymouth Meeting, PA 19462

    (484)-474-9991

    Radnor

    150 N. Radnor Chester Rd. Suite F-200W Radnor, PA 19087

    (610)-557-1620

    Cherry Hill

    5 Perina Blvd Suite 701 Cherry Hill, NJ 08003

    (610)-541-2500

    FDA Adds Vision Loss (NAION) Warning to Ozempic, Mounjaro and Other GLP-1 Drugs

    Posted on | November 19, 2026 |

    On November 9, 2026, the U.S. Food and Drug Administration announced it is requiring a new vision warning on every GLP-1 diabetes and weight-loss drug, including Ozempic, Wegovy and Mounjaro. The FDA is ordering drugmakers to add information about non-arteritic anterior ischemic optic neuropathy (NAION), a rare but serious eye condition that can cause sudden vision loss, to the Warnings and Precautions section of their labels, according to the FDA’s Drug Safety Communication.

    For people who lost vision after taking one of these drugs, the warning is an important development, and it comes as lawsuits over GLP-1 vision loss move forward in federal court here in Philadelphia.

    Which Drugs Are Affected?

    The FDA’s requirement applies to the entire class of GLP-1 receptor agonists, including:

    • Ozempic, Wegovy and Rybelsus (semaglutide)
    • Mounjaro and Zepbound (tirzepatide)
    • Trulicity (dulaglutide)
    • Victoza and Saxenda (liraglutide)
    • Xultophy (liraglutide and insulin degludec)
    • Soliqua (lixisenatide and insulin glargine)
    • Foundayo (orforglipron)
    • Generic exenatide

    What Is NAION?

    NAION happens when blood flow to the optic nerve is reduced, damaging the nerve. It typically causes sudden, painless vision loss in one eye, which the FDA notes patients may first notice when they wake up. The World Health Organization describes NAION as a leading cause of vision loss in adults and says the vision loss is generally irreversible, with no effective treatment currently available, according to a 2025 WHO alert.

    What the FDA Found

    The FDA concluded there is a “potential increased risk” of NAION with GLP-1 drugs. Among the evidence it reviewed was an analysis of 126 clinical trials, in which NAION occurred at a rate of 6.4 cases per 100,000 person-years among patients taking a GLP-1 drug, compared with 3.8 among patients taking a placebo.

    The agency noted limits in the evidence. NAION is rare, many of its risk factors, such as diabetes, high blood pressure and sleep apnea, are common among people who take these drugs, and the FDA did not identify a biological mechanism in animal studies. Even so, it decided the potential risk was serious enough to require a warning across the entire drug class.

    Europe Acted First

    In June 2025, the European Medicines Agency’s safety committee concluded that NAION is a very rare side effect of the semaglutide drugs Ozempic, Rybelsus and Wegovy, meaning it may affect up to 1 in 10,000 people taking them, the EMA reported. European regulators advised that semaglutide treatment should be stopped if NAION is confirmed.

    What Patients Should Do

    • Watch for warning signs. Contact your doctor right away if you notice sudden vision loss, a blind spot, blurring or other vision changes, especially in one eye.
    • See an eye specialist. The FDA advises doctors to refer patients with suspected NAION promptly to an ophthalmologist.
    • Do not stop your medication on your own. The FDA says patients who develop NAION should talk with their health care professional about whether to continue or stop their GLP-1 drug.
    • Keep your records. Save your prescription and pharmacy records, the dates you started and stopped the drug, and all eye exams and diagnoses.
    • Report side effects. Patients and doctors can report problems to the FDA’s MedWatch program online or at 1-800-332-1088.

    What the New Warning Means for GLP-1 Vision Loss Lawsuits

    People who developed NAION after taking GLP-1 drugs have filed lawsuits against Novo Nordisk, the maker of Ozempic, Wegovy and Saxenda, and Eli Lilly, the maker of Trulicity, Mounjaro and Zepbound. In December 2025, federal vision loss cases were combined into a multidistrict litigation, MDL No. 3163, before Judge Karen S. Marston in the U.S. District Court for the Eastern District of Pennsylvania in Philadelphia, according to the court. It is the second MDL in that court involving GLP-1 drugs; a separate MDL covers gastrointestinal injuries.

    The lawsuits allege that the drugmakers failed to adequately warn patients and doctors about the risk of vision loss. Because these are failure-to-warn claims, what the drug labels said, and when, is central to the cases. The FDA’s decision to require a NAION warning is a significant development, though it does not by itself decide whether the companies are liable. The litigation is ongoing, and no outcome is guaranteed.

    Do You Have a GLP-1 Vision Loss Claim?

    You may have a claim if you or a loved one:

    • Took Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Victoza, Saxenda or another GLP-1 drug, and
    • Were later diagnosed with NAION or suffered sudden vision loss

    Legal deadlines apply, and the time to file can depend on when you were diagnosed and when you learned your vision loss may be linked to the drug. Do not wait to get advice.

    Talk to a Philadelphia GLP-1 Vision Loss Lawyer

    Wieand Parker Arreola, PLLC, is based in Center City Philadelphia, close to the federal courthouse where MDL 3163 is being litigated. We represent people in Pennsylvania and New Jersey who were harmed by dangerous drugs. Call (215) 666-7777 or contact us online for a free consultation. Learn more on our Ozempic vision loss lawsuit page and our defective drug page.

    This article provides general information and is not legal or medical advice. Do not stop or change any medication without talking to your doctor. Reading this article does not create an attorney-client relationship. Prior results do not guarantee a similar outcome.

    When AI Causes Harm: Who Can Be Held Liable, and How to Prove It
    Previous

    When AI Causes Harm: Who Can Be Held Liable, and How to Prove It

    Next

    When Driver-Assist Fails: Can the Car Manufacturer Be Held Liable?

    When Driver-Assist Fails: Can the Car Manufacturer Be Held Liable?

    INSIGHTS & BLOGS

    Recent Posts

    When AI Causes Harm: Who Can Be Held Liable, and How to Prove It

    When AI Causes Harm: Who Can Be Held Liable, and How to Prove It

    When Driver-Assist Fails: Can the Car Manufacturer Be Held Liable?

    When Driver-Assist Fails: Can the Car Manufacturer Be Held Liable?

    Waymo Pulls Robotaxis Off U.S. Freeways: What It Means for Philadelphia

    Waymo Pulls Robotaxis Off U.S. Freeways: What It Means for Philadelphia